Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

FDA Approves Seattle Genetics Drug for Two Cancers

By Pharmaceutical Processing | August 22, 2011

WASHINGTON (AP) — Federal regulators have approved an innovative cancer drug from Seattle Genetics Inc. to treat two rare forms of cancer that attack the lymph nodes.

The Food and Drug Administration on Friday approved Adcetris to treat Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma. Adcetris uses a targeted antibody to deliver the drug directly to cancerous tumor cells, sparing healthy cells.

The FDA approved the drug for patients who have already tried treating their disease with a bone marrow transplant or multiple rounds of chemotherapy.

About 8,800 new cases of Hodgkin’s disease are expected to be diagnosed this year, according to the National Cancer Institute. Adcetris is the first drug approved for the disease since 1977.

The FDA approved the drug under an accelerated, six month system reserved for therapies that show promising early results.

In a study of 102 patients with Hodgkin’s lymphoma, 73 percent of patients taking the drug saw their tumors shrink or disappear completely. On average, these patients responded to the drug for more than six months.

The approval for large cell lymphoma was based on a 58 patient study in which 86 percent of patients responded to the drug for over one year, on average.

The FDA’s accelerated approval program has come under criticism in the last year after multiple follow-up studies showed the popular cancer drug Avastin did not extend the lives of patients with breast cancer. The FDA granted the drug accelerated approval for that indication based on a single study. The FDA is now in the process of trying to remove the drug’s indication. The drug’s maker, Roche, has appealed the decision.

Seattle Genetics said in a statement it is working with the FDA on follow-up trials to confirm the benefits of Adcetris.

The Seattle-based biotech drugmaker will market the injectable drug in the U.S. and Canada, while Takeda Group holds marketing rights for the rest of the world.

Shares of Seattle Genetics rose 41 cents, or 2.9 percent, to $14.36 in afternoon trading.

 

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE